Pharmabiz
 

Scientists get US patent on deriving diabetes mellitus therapeutic agent from Piper longum

Joe C Mathew, New DelhiFriday, August 18, 2006, 08:00 Hrs  [IST]

The scientists associated with Council of Scientific and Industrial Research (CSIR) has received a US patent for the development of a novel process to isolate alpha-glucosidase inhibitory agent from the plant source Piper longum in significant yields. The pharmaceutical composition comprising the alpha-glucosidase inhibitory agent selected from pipataline (formula 1a), sesamin (formula 1b), pellitorine (Formula 1c), guineensine (Formula 1d) and brachystamide-B (formula 1e) have been shown having therapeutic application for diabetes mellitus, cancer, viral diseases such as hepatitis B and C, HIV, AIDS etc. The inventors Janaswamy Madhusudana Rao, Pullela Venkata Srinivas, Vummenthala Anuradha, Ashok Kumar Tiwari, Amtul Zehra Ali, Jhillu Singh Yadav and Kondapuram Vijaya Raghavan had applied for the US patent four years ago. The present invention embodies the isolation of pipataline, sesamin, pellitorine, guineensine, brachystamide-B as alpha-glucosidase inhibitory principles from Piper longum among which pipataline is from an entirely new source. CSIR is one of the world's leading scientific institutions when it comes to number of US patents. It bags more number of patents than any other scientific body in the country.

 
[Close]